.Attributes Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a typical follow-up of 11 months, clients with metastatic intestinal lumps that received biomarker-matched therapies based upon distributing growth DNA profiling showed a higher scientific advantage than those receiving unrivaled treatment.